Hearing loss among survivors of childhood brain tumors treated with an irradiation‐sparing approach
Authors:
- Etan OrgelEOEtan Orgel
- Shveta JainSJShveta Jain
- Lingyun JiLJLingyun Ji
- Liora PollickLPLiora Pollick
- Stephanie SiSSStephanie Si
- Jonathan FinlayJFJonathan Finlay
- David R. FreyerDFDavid R. Freyer
- 27 July 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 58 (6) , 953-958
Abstract
Background: Intensive, irradiation‐sparing chemotherapy regimens for malignant brain tumors have improved survival and neurocognitive outcomes in very young children. Platinum compounds are pivotal to this approach's success but are associated with hearing loss that markedly reduces quality of life for survivors. The purpose of this study was to determine the prevalence and severity of ototoxicity associated with Head Start and similar irradiation‐sparing regimens.Procedure: A retrospective cohort study was conducted of children treated for malignant brain tumors at Children's Hospital Los Angeles using irradiation‐sparing regimens. Patient and treatment characteristics were ascertained. Primary outcomes were post‐treatment hearing status, need for hearing aids, and hearing threshold change.Results: Twenty‐nine patients were evaluable. The most common diagnosis was medulloblastoma (n = 14). The median age at diagnosis was 2.0 years (range, 0.2–9.2). Median time from diagnosis to most recent hearing assessment was 1.1 years (mean 2.4; range, 0.2–17.5). Cumulative cisplatin and carboplatin dose was 281 ± 88 mg/m2 and 1,205 ± 277 mg/m2, respectively. All patients had aminoglycoside exposure. Following treatment, 18 patients (62.1%) had abnormal hearing and 11 (37.9%) required hearing aids. At 4,000 Hz, statistically significant hearing loss was documented in the range of 30–40 dB.Conclusions: While eliminating cranial irradiation has dramatically improved survival and neurocognitive and neuroendocrine outcomes in this population, clinically significant hearing loss is now the leading late effect due to the necessity of platinum‐based chemotherapy. Our results document the need for audiometric monitoring and developing otoprotective strategies in this vulnerable population. Pediatr Blood Cancer 2012; 58: 953–958.Keywords
This publication has 37 references indexed in Scilit:
- Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocolsPediatric Blood & Cancer, 2008
- Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experiencePediatric Blood & Cancer, 2007
- Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescuePediatric Blood & Cancer, 2007
- New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2006
- Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastomaCancer, 2006
- Neurocognitive Consequences of Risk-Adapted Therapy for Childhood MedulloblastomaJournal of Clinical Oncology, 2005
- Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated MedulloblastomaJournal of Clinical Oncology, 2004
- Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapyNeuro-Oncology, 2004
- Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER updateMedical and Pediatric Oncology, 2002
- Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.Journal of Clinical Oncology, 1998